Cell Genesys Announces Encouraging Results From Phase 1/2 Trial Of GVAX Immunotherapy For Prostate Cancer In Recurrent Disease

Cell Genesys, Inc. (Nasdaq:CEGE) announced data from a completed Phase 1/2 clinical trial (G-9802) of GVAX immunotherapy for prostate cancer in men with recurrent prostate cancer who had not yet received treatment with hormone replacement therapy following relapse after prostate cancer surgery and/or radiation therapy.

More: continued here

Filed under: Prostate on April 17th, 2008